Cosentyx One-Click Enrolment

By providing your personal information to Novartis Pharmaceuticals Australia Pty Ltd or its related bodies corporate (Novartis), you consent to Novartis collecting, storing and using your personal information in accordance with the Novartis Privacy Policy at https://www.novartis.com.au/privacy-policy. In particular, you consent to Novartis using your personal information to communicate with you about Novartis products and/or to support your use of those products, and you consent to Novartis using your personal information for audit or inspection purposes. Novartis reserves the right to use aggregated and de-identified data collected through this Activity. You also consent to Novartis using your personal information to (where applicable) invite you to, or arrange your participation in, activities managed by (or on behalf of) Novartis.

Novartis has engaged third party service providers (Approved Contractors) for the purposes of administering the Altogether You Support Program (Activity). Approved Contractors, for the purposes of the Activity, may include Medical Safety Systems Corporate Pty Ltd trading as RxMx Australia (RxMx). You consent to the Approved Contractor(s) collecting, storing and using your personal information in connection with the Activity, including to organise your participation in the Activity or to communicate with you in relation to the Activity, in accordance with the Novartis Privacy Policy.

Novartis is committed to patient safety. In accordance with regulatory obligations for reporting safety information Novartis processes reports of adverse events experienced by patients on Novartis products when identified by a Novartis representative (or by a third party acting on behalf of Novartis). Novartis Patient Safety may contact you or your healthcare professional in order to collect further information on the adverse event. This information may be shared with health authorities or other pharmaceutical companies with whom Novartis has a license agreement, and third parties we work with for the purpose of safety reporting.

Your information may be stored on servers located in jurisdiction outside of Australia. Some of those countries may not offer the same level of privacy protection as in Australia. However, Novartis will enter into agreements with its third party service providers to keep your information secure and provide adequate protection for your data.

You are not obliged to provide personal information. However, if you do not provide information you may not, for example, be able to participate fully in activities managed by us.

You have the right to access, update or correct your personal information and/or decline to receive communications from Novartis. To find out how, please refer to https://www.novartis.com.au/privacy-policy or contact our Privacy Officer at Novartis Australia, Phone: 02 9805 3555, Email: privacy.au@novartis.com.

Adverse events: Very common (≥10%) nasopharyngitis. Common (≥1 to <10%): upper respiratory tract infection, rhinitis, pharyngitis, oral herpes, diarrhoea, urticaria, dermatitis (including eczema), rhinorrhoea, headache, nausea, hypercholesterolemia.

PBS Information: Section 85 Authority Required for the treatment of severe chronic plaque psoriasis, active ankylosing spondylitis, severe psoriatic arthritis, non-radiographic axial spondyloarthritis and hidradenitis suppurativa. Refer to PBS Schedule for full Authority information.

®Registered trademark of Novartis Pharmaceuticals.
Novartis Pharmaceuticals Australia Pty Limited. ABN 18 004 244 160. Sydney NSW. Ph +61 2 9805 3555. Date of prepartion: March 2026. AU-30162. RxPx.